Evogene Ltd. (EVGN) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Evogene Ltd. Do?
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Evogene Ltd. (EVGN) is classified as a micro-cap stock in the Materials sector, specifically within the Chemicals industry. The company is led by CEO Ofer Haviv and employs approximately 140 people. With a market capitalization of $8M, EVGN is one of the notable companies in the Materials sector.
Evogene Ltd. (EVGN) Stock Rating — Reduce (April 2026)
As of April 2026, Evogene Ltd. receives a Reduce rating with a composite score of 35.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.EVGN ranks #3,361 out of 4,446 stocks in our coverage universe. Within the Materials sector, Evogene Ltd. ranks #242 of 284 stocks, placing it in the lower half of its Materials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
EVGN Stock Price and 52-Week Range
Evogene Ltd. (EVGN) currently trades at $0.79. The stock lost $0.03 (3.6%) in the most recent trading session. The 52-week high for EVGN is $2.42, which means the stock is currently trading -67.3% from its annual peak. The 52-week low is $0.73, putting the stock 8.3% above its annual trough. Recent trading volume was 29K shares, suggesting relatively thin trading activity.
Is EVGN Overvalued or Undervalued? — Valuation Analysis
Evogene Ltd. (EVGN) carries a value factor score of 2/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 0.24x, compared to 0.74x for the average Materials stock.
At current multiples, Evogene Ltd. trades at a premium to most Materials peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Evogene Ltd. Profitability — ROE, Margins, and Quality Score
Evogene Ltd. (EVGN) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -181.2% versus the sector average of 0.6%.
On a margin basis, Evogene Ltd. reports gross margins of 68.5%, compared to 29.8% for the sector. The operating margin is -261.0% (sector: 6.0%). Net profit margin stands at -212.1%, versus 3.0% for the average Materials stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
EVGN Debt, Balance Sheet, and Financial Health
Balance sheet data for EVGN is evaluated through our stability factor. Total debt on the balance sheet is $12M. Cash and equivalents stand at $15M.
EVGN has a beta of 0.66, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Evogene Ltd. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Evogene Ltd. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Evogene Ltd. reported revenue of $9M and earnings per share (EPS) of $-2.89. Net income for the quarter was $-18M. Gross margin was 68.5%. Operating income came in at $-22M.
In FY 2024, Evogene Ltd. reported revenue of $9M and earnings per share (EPS) of $-2.89. Net income for the quarter was $-18M. Gross margin was 68.5%. Revenue grew 50.9% year-over-year compared to FY 2023. Operating income came in at $-22M.
In FY 2023, Evogene Ltd. reported revenue of $6M and earnings per share (EPS) of $-0.52. Net income for the quarter was $-26M. Gross margin was 70.0%. Revenue grew 236.7% year-over-year compared to FY 2022. Operating income came in at $-27M.
In FY 2022, Evogene Ltd. reported revenue of $2M and earnings per share (EPS) of $-6.44. Net income for the quarter was $-30M. Gross margin was 45.7%. Revenue grew 80.1% year-over-year compared to FY 2021. Operating income came in at $-27M.
Over the past 8 quarters, Evogene Ltd. has demonstrated a growth trajectory, with revenue expanding from $2M to $9M. Investors analyzing EVGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
EVGN Dividend Yield and Income Analysis
Evogene Ltd. (EVGN) does not currently pay a dividend. This is common among smaller companies in the Chemicals industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Materials dividend stocks may want to explore other Materials stocks or use the stock screener to filter by dividend yield.
EVGN Momentum and Technical Analysis Profile
Evogene Ltd. (EVGN) has a momentum factor score of 35/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 58/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.
EVGN vs Competitors — Materials Sector Ranking and Peer Comparison
Within the Materials sector, Evogene Ltd. (EVGN) ranks #242 out of 284 stocks based on the Blank Capital composite score. This places EVGN in the lower half of all Materials stocks in our coverage universe. Key competitors and sector peers include CF Industries Holdings, Inc. (CF) with a score of 56.6/100, Nutrien Ltd. (NTR) with a score of 56.6/100, CVR PARTNERS, LP (UAN) with a score of 55.6/100, LSB INDUSTRIES, INC. (LXU) with a score of 53.6/100, and ACME UNITED CORP (ACU) with a score of 51.2/100.
Comparing EVGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EVGN vs S&P 500 (SPY) comparison to assess how Evogene Ltd. stacks up against the broader market across all factor dimensions.
EVGN Next Earnings Date
No upcoming earnings date has been announced for Evogene Ltd. (EVGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy EVGN? — Investment Thesis Summary
The quantitative profile for Evogene Ltd. suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 2/100 indicates premium valuation. Momentum is weak at 35/100, a headwind for near-term performance. High volatility (stability score 32/100) increases portfolio risk.
In summary, Evogene Ltd. (EVGN) earns a Reduce rating with a composite score of 35.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EVGN stock.
Related Resources for EVGN Investors
Explore more research and tools: EVGN vs S&P 500 comparison, top Materials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EVGN head-to-head with peers: EVGN vs CF, EVGN vs NTR, EVGN vs UAN.